Favorable Press Coverage Somewhat Unlikely to Affect Clovis Oncology (NASDAQ:CLVS) Share Price

Press coverage about Clovis Oncology (NASDAQ:CLVS) has trended positive on Wednesday, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Clovis Oncology earned a media sentiment score of 0.33 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.5101026573113 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:

Shares of Clovis Oncology (NASDAQ CLVS) traded down $2.40 during mid-day trading on Wednesday, reaching $59.60. The company’s stock had a trading volume of 662,495 shares, compared to its average volume of 1,260,000. Clovis Oncology has a 52-week low of $45.42 and a 52-week high of $99.45. The company has a debt-to-equity ratio of 0.77, a quick ratio of 7.35 and a current ratio of 7.69. The company has a market capitalization of $2,920.00, a price-to-earnings ratio of -14.06 and a beta of 1.10.

Clovis Oncology (NASDAQ:CLVS) last released its earnings results on Monday, February 26th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.25. Clovis Oncology had a negative return on equity of 81.34% and a negative net margin of 624.02%. The company had revenue of $17.04 million during the quarter, compared to analyst estimates of $19.42 million. During the same quarter in the previous year, the company posted ($1.83) EPS. Clovis Oncology’s revenue for the quarter was up 21746.2% on a year-over-year basis. equities analysts expect that Clovis Oncology will post -4.75 earnings per share for the current fiscal year.

CLVS has been the subject of a number of recent research reports. BidaskClub raised Clovis Oncology from a “strong sell” rating to a “sell” rating in a report on Tuesday, March 6th. Stifel Nicolaus decreased their price target on Clovis Oncology from $125.00 to $110.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th. Cann reaffirmed a “hold” rating on shares of Clovis Oncology in a research note on Tuesday, February 27th. SunTrust Banks decreased their target price on Clovis Oncology from $95.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th. Finally, Barclays set a $85.00 price target on Clovis Oncology and gave the stock a “buy” rating in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $87.84.

In related news, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $59.16, for a total value of $177,480.00. Following the sale, the insider now owns 183,571 shares in the company, valued at approximately $10,860,060.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thorlef Spickschen sold 4,500 shares of the company’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $64.97, for a total value of $292,365.00. Following the completion of the sale, the director now owns 21,118 shares in the company, valued at approximately $1,372,036.46. The disclosure for this sale can be found here. Insiders have sold a total of 22,500 shares of company stock worth $1,371,210 in the last quarter. Company insiders own 12.50% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by Equities Focus and is the sole property of of Equities Focus. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.equitiesfocus.com/2018/03/14/clovis-oncology-clvs-given-daily-media-impact-score-of-0-33.html.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Insider Buying and Selling by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply